Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 15/20 | 0.79 |
| ▸ | PLK3 | Q9H4B4 | 9/20 | 0.79 |
| ▸ | PLK2 | Q9NYY3 | 7/20 | 0.79 |
| ▸ | BRD4 | O60885 | 12/20 | 0.79 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.79 |
| ▸ | TAF1 | P21675 | 5/20 | 0.79 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.79 |
| ▸ | CLK2 | P49760 | 3/20 | 0.79 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.79 |
| ▸ | CAMK2G | Q13555 | 3/20 | 0.79 |
| ▸ | CAMK2D | Q13557 | 3/20 | 0.79 |
| ▸ | PRKD2 | Q9BZL6 | 3/20 | 0.79 |
| ▸ | CSNK1G1 | Q9HCP0 | 3/20 | 0.79 |
| ▸ | CSNK1G3 | Q9Y6M4 | 3/20 | 0.79 |
| ▸ | BRDT | Q58F21 | 3/20 | 0.79 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.79 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.79 |
| ▸ | EGFR | P00533 | 2/20 | 0.79 |
| ▸ | FES | P07332 | 2/20 | 0.79 |
| ▸ | PHKG2 | P15735 | 2/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12360946 | 0.92 | PLK1 (0.77) | PLK1PLK3PLK2BRD4ALK | |
| SCHEMBL3567650 | 0.92 | PLK1 (0.84) | PLK1PLK3PLK2BRD4ALK | |
| SCHEMBL3777463 | 0.90 | PLK1 (0.73) | PLK1PLK3PLK2BRD4ALK | |
| SCHEMBL30750597 | 0.90 | PLK1 (0.83) | PLK1PLK3PLK2BRD4ALK | |
| SCHEMBL4239111 | 0.90 | PLK1 (0.83) | PLK1PLK3PLK2BRD4ALK | |
| SCHEMBL376040 | 0.90 | PLK1 (0.83) | PLK1PLK3PLK2BRD4ALK | |
| SCHEMBL3579332 | 0.90 | PLK1 (0.88) | PLK1PLK3PLK2BRD4ALK | |
| SCHEMBL375831 | 0.90 | PLK1 (0.72) | PLK1PLK3PLK2BRD4ALK | |
| SCHEMBL376153 | 0.89 | PLK1 (0.76) | PLK1PLK3PLK2BRD4ALK | |
| SCHEMBL13542018 | 0.89 | PLK1 (0.87) | PLK1PLK3PLK2BRD4ALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100004250-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-07 | — | — | US | disclosed |
| US-20100004250-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | CHROMA THERAPEUTICS LTD. (GB) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004250-A1 | PTERIDINE DERIVATIVES AS POLO-LIKE KINASE INHIBITORS USEFUL IN THE TREATMENT OF CANCER | PLK2, PLK4, PLK3 | PLK1 13/4885PLK3 3/4885PLK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.